|
Recordati, established in 1926, is a European pharmaceutical
group, listed on the Italian Stock Exchange (Reuters RECI.MI,
Bloomberg REC IM, ISIN IT 0003828271), dedicated to the research,
development, manufacturing and marketing of pharmaceuticals, with
headquarters in Milan, Italy, operations in the main European
countries, and a total staff of over 2,200. A European field force
of over 1,100 medical representatives promotes a wide range of
innovative pharmaceuticals, both proprietary and under license, in
a number of therapeutic areas. Recordati’s current and
growing coverage of the European pharmaceutical market makes it a
partner of choice for new product licenses from companies which do
not have European marketing organizations. Recordati is committed
to the research of new drug entities within the cardiovascular and
urogenital therapeutic areas in which its research team has proven
scientific competence and a track record of discovery and
development of original drugs, the most recent of which,
lercanidipine, a latest generation calcium channel blocker for the
treatment of hypertension, is the company’s leading product.
Consolidated revenue for 2007 was € 628.4 million, operating
income was € 131.5 million and net income was € 84.9
million.
|